Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Scheid C, Jablonski J, Kerkhoff A, Stelljes M, Trautmann-Grill K, Bornhäuser M, Tischer JM, von Bergwelt-Baildon M, Janson D, Ayuk F, Kröger N, Holtick U, Richardson T, von Tresckow B, Fuchs M, Borchmann P, Bröckelmann PJ

Open source

DOI: 10.1182/bloodadvances.2026020136
Published: 2026 Aug 25
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026020136,
  title = {Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.},
  author = {Scheid C and Jablonski J and Kerkhoff A and Stelljes M and Trautmann-Grill K and Bornhäuser M and Tischer JM and von Bergwelt-Baildon M and Janson D and Ayuk F and Kröger N and Holtick U and Richardson T and von Tresckow B and Fuchs M and Borchmann P and Bröckelmann PJ},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026020136},
  url = {https://doi.org/10.1182/bloodadvances.2026020136}
}

RIS

TY  - JOUR
TI  - Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.
AU  - Scheid C
AU  - Jablonski J
AU  - Kerkhoff A
AU  - Stelljes M
AU  - Trautmann-Grill K
AU  - Bornhäuser M
AU  - Tischer JM
AU  - von Bergwelt-Baildon M
AU  - Janson D
AU  - Ayuk F
AU  - Kröger N
AU  - Holtick U
AU  - Richardson T
AU  - von Tresckow B
AU  - Fuchs M
AU  - Borchmann P
AU  - Bröckelmann PJ
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026020136
UR  - https://doi.org/10.1182/bloodadvances.2026020136
ER  -

APA

C, S., J, J., A, K., M, S., K, T., M, B., JM, T., M, V. B., D, J., F, A., N, K., U, H., T, R., B, V. T., M, F., P, B., & PJ, B. (2026). Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020136

Source records

pubmed · retrieved 2026-09-26T14:32:57.390Z